Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beltavac subcutaneous immunotherapy for house dust mite allergic rhinitis/rhinoconjunctivitis
2026-526105-15-00Phase 3Authorised
- Sponsor
- Probelte Pharma
- Start
- Jul 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma comparing Beltavac arm with Placebo arm (2 arms). Primary endpoint: Combined score of nasal symptoms and specific allergy medication (CSMR4). Planned start Jul 2026; status: authorised.
02
Drugs
Beltavac
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2026-526105-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526105-15-00.